Home > Research Institute > Available Trials > Phase 3 study of tafasitamab plus lenalidomide with R-CHOP vs R-CHOP in DLBCL
Phase 3 study of tafasitamab plus lenalidomide with R-CHOP vs R-CHOP in DLBCL
A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma
Disease Types: Lymphoma
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma
For more information: